Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post

Par Drugs & Chemicals Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹76.60Overvalued by 15.08%vs CMP ₹90.20

P/E (8.0) × ROE (13.6%) × BV (₹86.50) × DY (2.00%)

₹121.47Undervalued by 34.67%vs CMP ₹90.20
MoS: +25.7% (Adequate)Confidence: 54/100 (Moderate)Models: 5 Under, 4 Fair
ModelCategoryValueWeightSignal
PE-ROEEarnings₹83.1822%Fair (-7.8%)
Graham NumberEarnings₹148.3616%Under (+64.5%)
Earnings PowerEarnings₹86.9013%Fair (-3.7%)
DCFCash Flow₹178.6213%Under (+98%)
Net Asset ValueAssets₹86.147%Fair (-4.5%)
EV/EBITDAEnterprise₹156.029%Under (+73%)
Earnings YieldEarnings₹113.107%Under (+25.4%)
ROCE CapitalReturns₹158.999%Under (+76.3%)
Revenue MultipleRevenue₹82.075%Fair (-9%)
Consensus (9 models)₹121.47100%Undervalued

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 8.6%

*Investments are subject to market risks

Analyst Summary

Par Drugs & Chemicals Ltd operates in the Pharmaceuticals segment, current market price is ₹90.20, market cap is 111 Cr.. At a glance, stock P/E is 7.98, ROE is 13.6 %, ROCE is 18.4 %, book value is 86.5, dividend yield is 0.00 %. The latest intrinsic value estimate is ₹121.47, which is about 34.7% above the current price, so the page currently reads as potentially undervalued rather than fully priced. On operating trend, latest reported sales are about ₹101 Cr versus the prior period change of 5.2%, while latest net profit is about ₹13 Cr with a prior-period change of -7.1%. The 52-week range shown on this page is 122/78.0, which helps frame where the current quote sits within its recent trading band. Business context: About the Company - Qualitative AnalysisPar Drugs & Chemicals Ltd. is a Public Limited Listed company incorporated on 26/02/1999 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is…

This summary is generated from the stock page data available for Par Drugs & Chemicals Ltd: Intrinsic Value & Share Price Analysis and is refreshed automatically when the underlying metrics change.

Investment Snapshot

64
Par Drugs & Chemicals Ltd scores 64/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health81/100 · Strong
ROCE 18.4% GoodROE 13.6% GoodD/E 0.14 Low debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money50/100 · Moderate
FII holding stable No changePromoter holding at 73.4% Stable
Earnings Quality60/100 · Moderate
OPM stable around 22% SteadyWorking capital: 39 days (improving) Efficient
Quarterly Momentum50/100 · Moderate
Revenue (4Q): 5% YoY FlatProfit (4Q): -10% YoY DecliningOPM: 20.6% (up 13.9% YoY) Margin expansion
Industry Rank65/100 · Strong
P/E 8.0 vs industry 60.2 Cheaper than peersROCE 18.4% vs industry 16.5% Average3Y sales CAGR: 10% Moderate

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: May 5, 2026, 12:49 am

Market Cap 111 Cr.
Current Price 90.2
Intrinsic Value₹121.47
High / Low 122/78.0
Stock P/E7.98
Book Value 86.5
Dividend Yield0.00 %
ROCE18.4 %
ROE13.6 %
Face Value 10.0
PEG Ratio0.93

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Par Drugs & Chemicals Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Par Drugs & Chemicals Ltd 111 Cr. 90.2 122/78.07.98 86.50.00 %18.4 %13.6 % 10.0
Concord Drugs Ltd 111 Cr. 84.2 92.5/29.0209 26.10.00 %4.73 %0.88 % 10.0
Pharmaids Pharmaceuticals Ltd 105 Cr. 29.7 73.4/27.1 14.70.00 %17.4 %16.3 % 10.0
Bal Pharma Ltd 121 Cr. 75.5 113/59.714.9 49.21.59 %10.1 %9.66 % 10.0
Achyut Healthcare Ltd 124 Cr. 5.26 6.80/3.18288 1.340.00 %2.26 %1.77 % 1.00
Industry Average20,594.11 Cr1,138.8760.16202.220.35%16.48%15.27%6.10

All Competitor Stocks of Par Drugs & Chemicals Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 22.9324.4922.9325.8924.0022.8222.6134.6621.3822.3326.0528.6629.34
Expenses 19.7019.1018.7918.5318.7716.7218.3723.2519.9519.9022.4922.6023.29
Operating Profit 3.235.394.147.365.236.104.2411.411.432.433.566.066.05
OPM % 14.09%22.01%18.05%28.43%21.79%26.73%18.75%32.92%6.69%10.88%13.67%21.14%20.62%
Other Income 0.040.030.010.050.23-0.050.071.020.270.791.840.481.33
Interest 0.030.030.020.030.020.050.020.030.010.020.020.050.01
Depreciation 0.740.850.830.850.870.890.900.910.910.920.900.940.93
Profit before tax 2.504.543.306.534.575.113.3911.490.782.284.485.556.44
Tax % 25.20%24.01%25.15%25.27%25.16%27.20%25.07%25.15%24.36%27.63%25.67%25.59%25.47%
Net Profit 1.873.452.474.893.423.722.538.600.581.653.334.134.80
EPS in Rs 1.522.802.013.972.783.022.066.990.471.342.713.363.90

Last Updated: March 3, 2026, 3:53 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 25, 2026, 8:16 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 2733334942465661759696101106
Expenses 20262640343846455978738188
Operating Profit 7778889161618232018
OPM % 27%22%22%17%19%18%17%26%22%19%24%19%17%
Other Income 0000000200024
Interest 4442221100000
Depreciation 2233333333344
Profit before tax 1113336151315201819
Tax % 40%27%58%42%42%24%21%21%27%25%26%26%
Net Profit 110223512911141314
EPS in Rs 1.331.650.783.432.782.793.879.447.499.2111.7810.8611.31
Dividend Payout % 0%0%0%0%0%0%32%0%0%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)0.00%-100.00%0.00%50.00%66.67%140.00%-25.00%22.22%27.27%-7.14%
Change in YoY Net Profit Growth (%)0.00%-100.00%100.00%50.00%16.67%73.33%-165.00%47.22%5.05%-34.42%

Par Drugs & Chemicals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:12%
5 Years:13%
3 Years:10%
TTM:10%
Compounded Profit Growth
10 Years:31%
5 Years:23%
3 Years:13%
TTM:-3%
Stock Price CAGR
10 Years:%
5 Years:33%
3 Years:-17%
1 Year:-58%
Return on Equity
10 Years:16%
5 Years:17%
3 Years:17%
Last Year:14%

Last Updated: September 5, 2025, 12:05 pm

Balance Sheet

Last Updated: May 6, 2026, 4:00 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 333334661212121212
Reserves 89911122534464859738794
Borrowings 4438363129126800000
Other Liabilities 791012101113161918162021
Total Liabilities 61595856545160767989102119128
Fixed Assets 47454342393634303438413938
CWIP 0000001500000
Investments 000000000002527
Other Assets 14131514151525424450605563
Total Assets 61595856545160767989102119128

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 5979428128132016
Cash from Investing Activity + -6-0-0-2-1-0-10-3-7-6-25
Cash from Financing Activity + 2-9-5-8-4-212-10000
Net Cash Flow 1-11-10-0714-5614-9
Free Cash Flow -196742612461415
CFO/OP 77%127%91%116%59%34%90%98%66%97%108%106%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-37.00-31.00-29.00-23.00-21.00-4.003.008.0016.0018.0023.0020.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 1048381617567817590655260
Inventory Days 129111158698381455060494558
Days Payable 17118418313510794961121357358104
Cash Conversion Cycle 621057-55155301314404015
Working Capital Days 1026166-46-2613392461504039
ROCE %10%9%12%11%12%16%25%22%23%25%18%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 74.21%74.21%74.21%74.21%74.21%74.21%73.37%73.37%73.37%73.37%73.37%73.41%
FIIs 0.00%0.00%0.00%0.07%0.07%0.32%0.09%0.00%0.00%0.00%0.00%0.00%
DIIs 0.00%0.00%0.00%0.00%0.05%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Public 25.79%25.79%25.79%25.73%25.68%25.47%26.54%26.63%26.63%26.63%26.63%26.59%
No. of Shareholders 5,5855,6865,9027,0207,4038,0228,75717,18915,47214,88714,28013,761

Shareholding Pattern Chart

No. of Shareholders

Par Drugs & Chemicals Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 10.8611.789.217.4918.87
Diluted EPS (Rs.) 10.8611.789.217.4918.87
Cash EPS (Rs.) 13.8214.5811.8410.1523.45
Book Value[Excl.RevalReserv]/Share (Rs.) 80.4469.5957.9048.6684.87
Book Value[Incl.RevalReserv]/Share (Rs.) 80.4469.5957.9048.6684.87
Dividend / Share (Rs.) 0.000.000.001.250.00
Revenue From Operations / Share (Rs.) 82.0677.7377.8161.0198.75
PBDIT / Share (Rs.) 17.6018.7414.9913.3626.34
PBIT / Share (Rs.) 14.6315.9512.3610.6921.75
PBT / Share (Rs.) 14.5715.8612.2510.3220.71
Net Profit / Share (Rs.) 10.8611.799.217.4918.87
PBDIT Margin (%) 21.4424.1119.2621.8926.66
PBIT Margin (%) 17.8320.5115.8817.5222.02
PBT Margin (%) 17.7520.4015.7416.9220.97
Net Profit Margin (%) 13.2215.1611.8312.2719.11
Return on Networth / Equity (%) 13.4916.9315.9115.3822.23
Return on Capital Employeed (%) 17.5122.0020.3120.6122.15
Return On Assets (%) 11.1814.2712.7511.7015.20
Long Term Debt / Equity (X) 0.000.000.000.000.08
Total Debt / Equity (X) 0.000.000.000.000.14
Asset Turnover Ratio (%) 0.911.001.140.960.89
Current Ratio (X) 3.314.793.532.932.58
Quick Ratio (X) 2.944.463.152.612.39
Inventory Turnover Ratio (X) 19.646.978.137.687.47
Dividend Payout Ratio (NP) (%) 0.000.000.0016.690.00
Dividend Payout Ratio (CP) (%) 0.000.000.0012.310.00
Earning Retention Ratio (%) 0.000.000.0083.310.00
Cash Earning Retention Ratio (%) 0.000.000.0087.690.00
Interest Coverage Ratio (X) 263.72215.31138.4836.1925.22
Interest Coverage Ratio (Post Tax) (X) 163.70136.4086.0921.2815.99
Enterprise Value (Cr.) 76.93228.45150.02180.3662.64
EV / Net Operating Revenue (X) 0.762.391.572.401.03
EV / EBITDA (X) 3.559.918.1310.973.87
MarketCap / Net Operating Revenue (X) 1.032.771.802.621.25
Retention Ratios (%) 0.000.000.0083.300.00
Price / BV (X) 1.063.102.423.281.46
Price / Net Operating Revenue (X) 1.032.771.802.621.25
EarningsYield 0.120.050.060.040.15

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Par Drugs & Chemicals Ltd. is a Public Limited Listed company incorporated on 26/02/1999 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L24117GJ1999PLC035512 and registration number is 035512. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 100.97 Cr. and Equity Capital is Rs. 12.30 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
Pharmaceuticals815, Nilamber Triumph, Vadodra Gujarat 390007Contact not found
Management
NamePosition Held
Mr. Falgun Vallabhbhai SavaniChairman & Managing Director
Mr. Jignesh Vallabhbhai SavaniExecutive Director & CEO
Mr. Pravin Manjibhai BhayaniIndependent Director
Mrs. Kajal Chintanbhai VaghaniIndependent Director
Mrs. Krishna Mitulbhai ShahIndependent Director
Mrs. Bintal Bhaveshkumar ShahIndependent Director

FAQ

What is the intrinsic value of Par Drugs & Chemicals Ltd and is it undervalued?

As of 09 May 2026, Par Drugs & Chemicals Ltd's intrinsic value is ₹121.47, which is 34.67% higher than the current market price of ₹90.20, suggesting the stock is undervalued. This is calculated using the PE ratio method factoring in ROE (13.6 %), book value (₹86.5), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Par Drugs & Chemicals Ltd?

Par Drugs & Chemicals Ltd is trading at ₹90.20 as of 09 May 2026, with a FY2026-2027 high of ₹122 and low of ₹78.0. The stock is currently in the middle of its 52-week range. Market cap stands at ₹111 Cr..

How does Par Drugs & Chemicals Ltd's P/E ratio compare to its industry?

Par Drugs & Chemicals Ltd has a P/E ratio of 7.98, which is below the industry average of 60.16. Trading at a steep discount to peers could signal a value opportunity or reflect concerns about the company's fundamentals.

Is Par Drugs & Chemicals Ltd financially healthy?

Key indicators for Par Drugs & Chemicals Ltd: ROCE of 18.4 % indicates efficient capital utilization. Dividend yield is 0.00 %.

Is Par Drugs & Chemicals Ltd profitable and how is the profit trend?

Par Drugs & Chemicals Ltd reported a net profit of ₹13 Cr in Mar 2025 on revenue of ₹101 Cr. Compared to ₹9 Cr in Mar 2022, the net profit shows an improving trend.

Does Par Drugs & Chemicals Ltd pay dividends?

Par Drugs & Chemicals Ltd has a dividend yield of 0.00 % at the current price of ₹90.20. The company is currently not paying meaningful dividends.

Last Updated: May 5, 2026, 12:49 am
Author: Getaka|Social: XLinkedIn
Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Par Drugs & Chemicals Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports